Wyeth-Pfizer Merger Jobs Update: Wyeth's Collegeville, PA Headquarters Will Remain Open
.jpg)
In a previous blog post, I suggested that there was much speculation about whether or not there would be substantial job losses at the various Wyeth sites throughout Pennsylvania after the Wyeth-Pfizer merger closes. As you may recall, company representatives were assuring Pennsylvania legislators that major job cuts and site closure weren’t likely.
Yesterday, Bernard Poussot, president of Wyeth Pharmaceuticals, sent a message telling employees the company’s Collegeville Headquarters, which employs about 4,000 people, would remain open after the deal closes on October 15, 2009. The fate of employees at other Pennsylvania-based Wyeth facilities remains uncertain.
While this may be good news for some employees at the Collegeville site, it is likely that a substantial number of jobs will be shed after the deal closes. Previously, Pfizer suggested that the combined company intends to shed about 20,000 jobs. I guess the good news is that all 4000 Wyeth employees won’t be losing their jobs!
Until next time...
Good Luck and Good Job Hunting!!!!!!!
For any of you preclinical Pfizer/Wyeth folks that may have been laid off after all or who are going to be laid off from the Collegetown, PA facility, Novartis is are looking for a PhD level researcher for our East Hanover, NJ location. We are seeking somone with proven expertise in the areas of preclinical applications of imaging modalities like MR imaging and spectroscopy, X-ray microCT, ultrasound and/or optical imaging.
The candidate will be responsible for an experimental laboratory and the management of technical staff, as well as for subsequent development, implementation and management of experimental studies. The primary deliverable of this laboratory will be to enable in vitro and in vivo imaging of small animals (current internal focus on ultrasound, but in the future to include broader spectrum of imaging opportunities) in principal support for the early identification and characterization of toxicities during preclinical phases of drug development.